Improving the Recognition, Diagnosis, and Treatment of Hereditary Transthyretin Amyloidosis

To participate in this activity, please:

Log in Sign Up

Hereditary transthyretin amyloidosis (ATTRv) is a progressive disease impacting multiple organ systems, commonly associated with polyneuropathy and cardiomyopathy. The availability of disease-modifying therapies that improve patient and caregiver burden of disease underscores the importance of a timely diagnosis. While clinically challenging to identify, recognition of red flag symptoms can hasten diagnosis. In this activity, Michelle Kaku, MD, provides a summary of ATTRv, its diagnosis, and currently available disease-modifying therapies, including the clinical evidence supporting their use, and recommendations for patient monitoring. 

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2025-05-15
Closes: 2026-05-15

Target Audience:

This activity was developed for clinicians (MDs/DOs, NPs, PAs, nurses, pharmacists, geneticists) throughout the United States who are engaged in primary care or specialist care related to neurology, cardiology, or amyloidosis.

This activity is supported by an independent grant from Alnylam.

Accreditation Information

    Presenting Faculty

  • Michelle Kaku, MD headshot

    Michelle Kaku, MD

    Associate Professor of Neurology
    Vice Chair for Education, Neurology Department
    Icahn School of Medicine at Mount Sinai
    New York, New York